340 related articles for article (PubMed ID: 38250858)
1. Harnessing Immunity to Treat Advanced Thyroid Cancer.
Komatsuda H; Kono M; Wakisaka R; Sato R; Inoue T; Kumai T; Takahara M
Vaccines (Basel); 2023 Dec; 12(1):. PubMed ID: 38250858
[TBL] [Abstract][Full Text] [Related]
2. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
3. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
4. Crosstalk between Thyroid Carcinoma and Tumor-Correlated Immune Cells in the Tumor Microenvironment.
Song M; Liu Q; Sun W; Zhang H
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345200
[TBL] [Abstract][Full Text] [Related]
5. New Insights into Immune Cells and Immunotherapy for Thyroid Cancer.
Tao Y; Li P; Feng C; Cao Y
Immunol Invest; 2023 Nov; 52(8):1039-1064. PubMed ID: 37846977
[TBL] [Abstract][Full Text] [Related]
6. Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L; Feng Q; Wang J; Tan Z; Li Q; Ge M
Biochim Biophys Acta Rev Cancer; 2023 Jul; 1878(4):188928. PubMed ID: 37257629
[TBL] [Abstract][Full Text] [Related]
7. Target Therapy in Thyroid Cancer: Current Challenge in Clinical Use of Tyrosine Kinase Inhibitors and Management of Side Effects.
Puliafito I; Esposito F; Prestifilippo A; Marchisotta S; Sciacca D; Vitale MP; Giuffrida D
Front Endocrinol (Lausanne); 2022; 13():860671. PubMed ID: 35872981
[TBL] [Abstract][Full Text] [Related]
8. Molecular Targeted Therapies of Aggressive Thyroid Cancer.
Ferrari SM; Fallahi P; Politti U; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A
Front Endocrinol (Lausanne); 2015; 6():176. PubMed ID: 26635725
[TBL] [Abstract][Full Text] [Related]
9. Perspectives on the Treatment of Advanced Thyroid Cancer: Approved Therapies, Resistance Mechanisms, and Future Directions.
Porter A; Wong DJ
Front Oncol; 2020; 10():592202. PubMed ID: 33569345
[TBL] [Abstract][Full Text] [Related]
10. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin.
Fallahi P; Ferrari SM; Elia G; Ragusa F; Patrizio A; Paparo SR; Marone G; Galdiero MR; Guglielmi G; Foddis R; Cristaudo A; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():203-216. PubMed ID: 32569821
[TBL] [Abstract][Full Text] [Related]
11. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy.
Liu Y; Wang J; Hu X; Pan Z; Xu T; Xu J; Jiang L; Huang P; Zhang Y; Ge M
Drug Resist Updat; 2023 May; 68():100939. PubMed ID: 36806005
[TBL] [Abstract][Full Text] [Related]
13. Novel targeted therapies and immunotherapy for advanced thyroid cancers.
Naoum GE; Morkos M; Kim B; Arafat W
Mol Cancer; 2018 Feb; 17(1):51. PubMed ID: 29455653
[TBL] [Abstract][Full Text] [Related]
14. Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
Viola D; Valerio L; Molinaro E; Agate L; Bottici V; Biagini A; Lorusso L; Cappagli V; Pieruzzi L; Giani C; Sabini E; Passannati P; Puleo L; Matrone A; Pontillo-Contillo B; Battaglia V; Mazzeo S; Vitti P; Elisei R
Endocr Relat Cancer; 2016 Apr; 23(4):R185-205. PubMed ID: 27207700
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy in anaplastic thyroid cancer.
Ma M; Lin B; Wang M; Liang X; Su L; Okose O; Lv W; Li J
Am J Transl Res; 2020; 12(3):974-988. PubMed ID: 32269728
[TBL] [Abstract][Full Text] [Related]
16. Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.
Narayanan S; Colevas AD
Curr Treat Options Oncol; 2016 Jun; 17(6):30. PubMed ID: 27139457
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapy in Thyroid Cancer: State of the Art.
Valerio L; Pieruzzi L; Giani C; Agate L; Bottici V; Lorusso L; Cappagli V; Puleo L; Matrone A; Viola D; Romei C; Ciampi R; Molinaro E; Elisei R
Clin Oncol (R Coll Radiol); 2017 May; 29(5):316-324. PubMed ID: 28318881
[TBL] [Abstract][Full Text] [Related]
18. Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective.
Nervo A; Retta F; Ragni A; Piovesan A; Gallo M; Arvat E
Cancer Manag Res; 2022; 14():3047-3062. PubMed ID: 36275786
[TBL] [Abstract][Full Text] [Related]
19. Immune Landscape of Thyroid Cancers: New Insights.
Menicali E; Guzzetti M; Morelli S; Moretti S; Puxeddu E
Front Endocrinol (Lausanne); 2020; 11():637826. PubMed ID: 33986723
[TBL] [Abstract][Full Text] [Related]
20. Advances in pharmacotherapy for advanced thyroid cancer of follicular origin (PTC, FTC). New approved drugs and future therapies.
Elia G; Ferrari SM; Ragusa F; Paparo SR; Mazzi V; Ulisse S; Benvenga S; Antonelli A; Fallahi P
Expert Opin Pharmacother; 2022 Apr; 23(5):599-610. PubMed ID: 35038965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]